BTG PLC (BTG.L)
378.70GBp
11:42am EDT
-0.90p (-0.24%)
379.60p
380.90p
382.20p
374.70p
491,468
762,932
426.00p
297.00p
BTG.L
About
Overall
| Beta: | 0.90 |
| Market Cap (Mil.): | £1,368.46 |
| Shares Outstanding (Mil.): | 360.50 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BTG.L | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 76.56 | 32.01 | 32.18 |
| EPS (TTM): | 0.05 | -- | -- |
| ROI: | 3.56 | 19.61 | 18.91 |
| ROE: | 3.92 | 20.45 | 19.87 |
BTG says interventional medicine buys could boost sales to $1 bln
LONDON - British pharmaceutical company BTG announced two deals on Thursday that it said could create an interventional medicine business with potential sales of $1 billion.
UPDATE 1-BTG says interventional medicine buys could boost sales to $1 bln
* Buys EKOS Corp, Nordion unit for combined initial $380 mln
BRIEF-BTG to buy targeted therapies arm of Nordion
LONDON, May 23 - BTG PLC : * Proposed acquisition of therasphere * To buy the targeted therapies division of nordion, for approximately US$200
BRIEF-BTG to buy blood clot treatment specialist EKOS
LONDON, May 23 - BTG PLC : * Acquisition of ekos * Has entered into an agreement to buy ekos corporation for an initial cash of
BTG vein treatment on track for potential 2014 launch
LONDON - BTG's Varisolve treatment for varicose veins has been accepted for review by the U.S. Food and Drug Administration, putting it on track for potential approval and launch during the first half of 2014.
BTG says FDA accepts Varisolve for review
LONDON, April 12 - Speciality pharmaceutical company BTG said on Friday its Varisolve treatment for varicose veins has been accepted for review by the U.S. Food & Drug Administration (FDA) and could be approved and launched during the first half of 2014.
BRIEF-BTG says delivered a strong financial performance
LONDON, April 4 - BTG PLC : * Delivered a strong financial performance and has achieved its key business
BRIEF-BTG submits Varisolve application to the FDA
LONDON, Feb 4 - BTG PLC : * Varisolve nda submitted to the FDA
BRIEF-BTG sees FY revenues at top end of guidance
LONDON, Jan 31 - BTG PLC : * Anticipates FY revenues for year to 31 March 2013 will be around the top end
STXNEWS LATAM-Idle Cargill plant to boost US profit margins at JBS -BTG
The U.S. beef operations of Brazil-based meatpacker JBS SA could post better-than-expected profit margins in 2013 after Cargill decided to idle its beef processing plant in Plainview, easing pressure on cattle costs, analysts at BTG Group told clients in a note.
Earnings vs. 
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Wright Reports
|
$449.00
|
|
Provider: Edison Investment Research
|
$10.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
